ASC Therapeutics - Crunchbase Company Profile & Funding

Overview

ASC Therapeutics

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About ASC Therapeutics

CB Rank

438805

ASC Therapeutics is a biotechnology company that focuses on discovering and developing cures for intractable diseases.

Founded

obfuscation

Private

Milpitas, California, United States

51-100

www.asctherapeutics.com

Biopharma

Biotechnology

Health Care

Key People

Ruhong Jiang: CEO
Past Role: Applied StemCell, Co-Founder and CEO
Oscar Segurado: Chief Medical Officer
Past Role: BD Biosciences, Vice President, Clinical Development and Medical Affairs

Details

Legal Name

ASC Therapeutics Inc.

Operating Status

Active

Company Type

For Profit

About the Company

ASC Therapeutics is a biotechnology company that focuses on discovering and developing cures for intractable diseases. The company was founded in 2008 and is based in Milpitas, California.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

ASC-618

A gene therapy targeting Hemophilia A, designed to provide a long-term solution by introducing a functional gene to correct the underlying cause of the disease.

ASC-930

A therapy in development for treating Graft-versus-Host Disease (GVHD), focusing on mitigating immune system reactions following transplant procedures.